[6-K] Trinity Biotech plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Trinity Biotech reported breakthrough clinical trial results for its redesigned continuous glucose monitoring (CGM) sensor, indicating a significant development in its product pipeline. The Form 6-K states the company issued a press release describing those trial results and filed it as Exhibit 99.1. The filing also discloses that on August 7, 2025 the company and certain subsidiaries amended and restated the credit agreement governing their term loan facility with Perceptive Credit Holdings III, L.P. and that a warrant to purchase American Depositary Shares was issued in connection with that agreement. Copies of the press release, the Sixth Amended and Restated Credit Agreement and the warrant certificate are included as Exhibits 99.1, 99.2 and 99.3.

Positive

• Breakthrough clinical trial results for the redesigned CGM sensor are announced and documented in Exhibit 99.1
• Amended and restated credit agreement with Perceptive Credit Holdings III, L.P. executed, showing updated financing arrangements (filed as Exhibit 99.2)

Negative

• Warrant issued to purchase American Depositary Shares (filed as Exhibit 99.3), which could lead to future share issuance
• Key commercial and financial terms not included in the 6-K summary; Exhibits must be reviewed for material details

Insights

Clinical/Industry Specialist

TL;DR: Breakthrough trial results are potentially material for product advancement and market positioning.

The filing expressly states that Trinity Biotech achieved "breakthrough clinical trial results" for its redesigned CGM sensor and furnished a press release as Exhibit 99.1. From a clinical development perspective, such language typically signals positive safety or performance outcomes, but the 6-K itself does not provide the trial data or endpoints. Investors and analysts should review Exhibit 99.1 for sample size, endpoints met, statistical significance and regulatory implications before assessing commercial impact.

Corporate Finance Analyst

TL;DR: Credit agreement was amended and a warrant issued; terms are not disclosed in the summary.

The 6-K confirms a Sixth Amended and Restated Credit Agreement and Guaranty dated August 7, 2025 with Perceptive Credit Holdings III, L.P., and notes a warrant to purchase American Depositary Shares issued in connection with that agreement. The document filed here does not include material economic terms such as principal amount, covenant changes, interest rates, maturity, warrant strike price or potential dilutive impact. Review of Exhibits 99.2 and 99.3 is necessary to evaluate liquidity, covenant relief or dilution implications.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

TRINITY BIOTECH PLC

(Name of Registrant)

IDA Business Park

Bray, Co. Wicklow, Ireland

 (Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐      

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):          

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):          

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐    No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-               

This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070).

 EXPLANATORY NOTE

On August 12, 2025, the Company issued a press release announcing breakthrough clinical trial results for its redesigned CGM sensor. The Company and certain of its subsidiaries also amended and restated the credit agreement governing the companies’ term loan facility with Perceptive Credit Holdings III, L.P on August 7, 2025. Copies of the press release, the amended and restated credit agreement and warrant certificate issued in connection therewith are filed herewith as Exhibits 99.1, 99.2 and 99.3.

EXHIBIT INDEX

Exhibit		Description
99.1		Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor.
99.2		Sixth Amended and Restated Credit Agreement and Guaranty, dated as of August 7, 2025.
99.3		Warrant to purchase American Depositary Shares of Trinity Biotech plc, dated August 7, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TRINITY BIOTECH PLC
		Trinity Biotech plc
		(Registrant)
	By:	/s/ Susan O’Connor
		Susan O’Connor
		Interim Chief Financial Officer

Date:  August 12, 2025

FAQ

What did Trinity Biotech (TRIB) disclose in this Form 6-K?

The company announced breakthrough clinical trial results for its redesigned CGM sensor and disclosed an amended and restated credit agreement with Perceptive Credit Holdings III, L.P., plus a warrant issuance.

Which exhibits were filed with the 6-K?

Exhibit 99.1 is the press release on the CGM trial results, Exhibit 99.2 is the Sixth Amended and Restated Credit Agreement and Guaranty, and Exhibit 99.3 is the warrant to purchase American Depositary Shares.

When was the credit agreement amended?

The filing states the credit agreement was amended and restated on August 7, 2025.

Does the 6-K include financial results or trial data?

No. The 6-K references a press release with trial results and files the press release as Exhibit 99.1; the 6-K summary itself does not include trial data or financial results.

What details are provided about the warrant?

The 6-K confirms a warrant to purchase American Depositary Shares was issued in connection with the amended credit agreement and is filed as Exhibit 99.3; no economic terms are included in the summary.